

Apoptosis in Colon Cancer (HT29) Cells Exposed to Estradiol Valerat

Farahmandlou N¹, Jusheghani F^{*2}, Karimi Ghezeli Z³

¹Department of Basic Sciences, Faculty of Pharmacy, Pharmaceutical Sciences Branch,
Islamic Azad University, Tehran, Iran.(IAUPS)

² Department of Genetics, Tehran Medical Sciences Branch,
Islamic Azad University, Tehran, Iran

³Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry,
Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran (IAUPS)

Abstract: *The recent studies have shown a link between estrogen and cancer cells proliferation. The aim of this study was to investigate the effects of estradiol valerate on apoptosis in colon cancer cells. In this laboratory-experimental study, colon cancer cells were exposed to different doses (0.001, 0.01, 0.1 and 1mg/ml) of estradiol valerate. MTT assay was used to measure cell viability in cancer cells. The data were statistically analyzed between groups using ANOVA. There was significant decrease in cell viability of colon cancer cells in groups exposed to 0.01, 0.1 and 1 mg/ml of estradiol valerate compared to control group (P<0.05). It can be concluded that estradiol valerate has cytotoxic effect on colon cancer and can induce apoptosis in colon cancer cells in cell culture.*

Keywords: *Estradiol valerate, Cell viability, HT29 Cells*

1. Introduction

Rectal cancer accounts for a relevant part of colorectal cancer cases, with a mortality of 4-10/100000 per year. [1] Estradiol, the predominant form of estrogen, also plays a critical role in sexual function. Estrogen receptors, as well as aromatase, the enzyme that converts testosterone to estrogen, are abundant in brain and other organs [2] Estrogen also have anticancer effects on various tissues including prostate. [3] Endogenous estradiol metabolites are equally anti-proliferative as tamoxifen in the context of human breast cancer cells. [4] Estrogen is also involved in carcinogenesis. The oncogenic effects of E2 have been investigated extensively in breast and ovarian cancers where hormone-receptor modulators are now an integral part of targeted treatment. On the other hand, little is known about the E2 preventive signaling in colorectal cancer. [5] The aim of this study was to investigate the effects of estradiol valerate on apoptosis in colon cancer cells.

2. Material and Methods

In this laboratory-experimental study, colon cancer cells were exposed to different doses (0.001, 0.01, 0.1 and 1mg/ml) of estradiol valerate. MTT assay was used to measure cell viability in cancer cells. The data were statistically analyzed between groups using ANOVA.

3. Results

Exposure of colon cancer cells to 0.001 mg/ml of estradiol valerate did not significantly change the cell viability in cancer cells compared with control group. However, there was significant decrease in cell viability of colon cancer cells in groups exposed to 0.01, 0.1 and 1 mg/ml of estradiol valerate compared to control group (P<0.05) (Figure I).




Fig. I. Optic density (indicating cell viability) in control and groups exposed to 0.001, 0.01, 0.1 and 1 mg/ml of estradiol valerate. * indicates significant difference at $P < 0.05$.

4. Discussion

Our findings indicated that estradiol valerate has cytotoxic effects on colon cancer cells in cell culture. Estradiol has been shown that has a role in cancer treatment. [6] In women with advanced breast cancer and acquired resistance to aromatase inhibitors, a daily dose of 6 mg of estradiol provided a similar clinical benefit rate as 30 mg, with fewer serious adverse events[7]. However, there are studies showing that estrogens may have carcinogenic effects. It is of interest that E concentrations were significantly lower in patients with recurrent ovarian cancer. [8] E2 was shown to potentiate NNK-induced inflammation, cell proliferation, thereby leading to lung tumorigenesis [9]. Thyroid cancer is also well coupled with estrogen. [10] The results demonstrate that estradiol treatment potentiates growth of laryngeal tumors in nude mice[11].

In line with our findings it has been reported that endogenous estrogen lowers gastric cancer incidence in women, and cancer patients treated with estrogens have a lower subsequent risk of gastric cancer. [12] It has also been shown that of 17 beta -estradiol has protective effects against the development of Helicobacter pylori-induced gastric cancer [13]. The findings suggest that 17beta-estradiol treatment dramatically inhibits progression of human colon cancer cells. [14] Research have demonstrated involving of different cellular molecular events for the protective effects of E2 against colon cancer growth. [15]

5. Conclusion

It can be concluded that estradiol valerate has cytotoxic effect on colon cancer and can induce apoptosis in colon cancer cells in cell culture.

6. Acknowledgment

We appreciate all who helped us to exert this study.

7. References

- [1] Berardi R, Maccaroni E, Onofri A, Morgese F, Torniai M, Tiberi M, et al. Locally advanced rectal cancer: the importance of a multidisciplinary approach. *World J Gastroenterol.* 2014;20(46):17279-87. <https://doi.org/10.3748/wjg.v20.i46.17279>

- [2] Schulster M, Bernie AM, Ramasamy R. The role of estradiol in male reproductive function. *Asian J Androl.* 2016;18(3):435-40.
<https://doi.org/10.4103/1008-682X.173932>
- [3] Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. *BMC Cancer.* 2010;10:244.
<https://doi.org/10.1186/1471-2407-10-244>
- [4] Seeger H, Huober J, Wallwiener D, Mueck AO. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. *Horm Metab Res.* 2004;36(5):277-80.
<https://doi.org/10.1055/s-2004-814480>
- [5] Marino M. Xenoestrogens challenge 17 β -estradiol protective effects in colon cancer. *World J Gastrointest Oncol.* 2014;6(3):67-73.
<https://doi.org/10.4251/wjgo.v6.i3.67>
- [6] Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Anticancer Drugs.* 2010;21(4):433-8.
<https://doi.org/10.1097/CAD.0b013e3283355211>
- [7] Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA. et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. *JAMA.* 2009;302(7):774-80.
<https://doi.org/10.1001/jama.2009.1204>
- [8] Chen FC, Oskay-Ozcelik G, Bühling KJ, Köpstein U, Mentze M, Lichtenegger W, et al. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. *Anticancer Res.* 2009;29(5):1575-8.
- [9] Chen RJ, Chang CY, Chang LW, Siao SH, Ho YS, Wu CH, Foo NP. et al. The regulation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumor promotion by estradiol in female A/J mice. *PLoS One.* 2014;9(3):e93152.
<https://doi.org/10.1371/journal.pone.0093152>
- [10] Hima S, Sreeja S. Modulatory role of 17 β -estradiol in the tumor microenvironment of thyroid cancer. *IUBMB Life.* 2016;68(2):85-96.
<https://doi.org/10.1002/iub.1462>
- [11] Somers KD, Koenig M, Schechter GL. Growth of head and neck squamous cell carcinoma in nude mice: potentiation of laryngeal carcinoma by 17 beta-estradiol. *J Natl Cancer Inst.* 1988;80(9):688-91.
<https://doi.org/10.1093/jnci/80.9.688>
- [12] Liu CJ, Kuo FC, Hu HM, Chen CY, Huang YB, Cheng KH, et al. 17 β -Estradiol inhibition of IL-6-Src and Cas and paxillin pathway suppresses human mesenchymal stem cells-mediated gastric cancer cell motility. *Transl Res.* 2014;164(3):232-43.
<https://doi.org/10.1016/j.trsl.2014.04.009>
- [13] Ohtani M, García A, Rogers AB, Ge Z, Taylor NS, Xu S, et al. Protective role of 17 beta -estradiol against the development of *Helicobacter pylori*-induced gastric cancer in INS-GAS mice. *Carcinogenesis.* 2007;28(12):2597-604
<https://doi.org/10.1093/carcin/bgm150>
- [14] Lai TY, Chen LM, Lin JY, Tzang BS, Lin JA, Tsai CH, et al. 17beta-estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. *Mol Cell Biochem.* 2010;342(1-2):63-70
<https://doi.org/10.1007/s11010-010-0469-7>

- [15] Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17 β -estradiol induces ER β up-regulation via p38/MAPK activation in colon cancer cells. *Biochem Biophys Res Commun.* 2007 ;359(1):102-7
<https://doi.org/10.1016/j.bbrc.2007.05.059>